Foundational Patent Covers Anti-Reflection Metamaterial Films and System Architecture
HALIFAX, NS / ACCESSWIRE / May 13, 2022 / Meta Materials Inc. (the 'Company' or 'META®') (NASDAQ:MMAT),(FSE:MMAT) a developer of high-performance functional materials and nanocomposites, today announced that the Company's wholly-owned, UK subsidiary, Medical Wireless Sensing ('MediWise'), has been granted the first U.S. patent (US 11,298,052 B2) for its glucoWISE® non-invasive glucose sensing system and related anti-reflection metamaterial films. This foundational patent covers the anti-reflecting metamaterial films, which enhance signal penetration through the skin, and different configurations of the sensing system for collecting biomarker readings at various locations on the body. Co-inventors are Dr. Georgios 'George' Palikaras, Dr. Efthymios 'Themos' Kallos, and Dr. Helena Cano-Garcia.
'The granting of this patent in the United States is a key milestone in our glucoWISE® development plan,' said Dr. Themos Kallos, META's co-founder and Chief Science Officer. 'This is our foundational patent on non-invasive biosensing using radio waves, built around the core idea of an ultrathin metamaterial film that acts as an anti-reflection coating for the skin, leading to increased signal penetration to the tissue. It paves the way for a completely painless radio-wave-based glucose sensing system in the U.S., which is currently home to more than 30 million people living with diabetes.'
Dr. Cano-Garcia, lead inventor, in the MediWise facility in London, UK
Sample broadband metamaterial film
The glucoWISE® system in development is intended to allow monitoring of blood glucose levels without the need for painful finger sticks. META plans to first introduce a table-top version of the device, for use at home or in the clinic, followed by a pocket-sized, portable version to allow quick, painless monitoring anywhere, and subsequently, a wearable version. In July 2021, META announced the completion of a UK-funded, 27-month project to develop a non-invasive glucose sensing prototype, which combined for the first time radio wave and optical sensors to improve accuracy in predicting glucose level changes. The development team has since expanded and is actively working on the next generation prototype, suitable for human studies in 2022.
'META's broad and rapidly growing intellectual property portfolio is a key element of our strategy to support growth and establish a durable competitive advantage,' said George Palikaras, President and CEO. 'Dr. Shann Kerner joined us last September as Chief Intellectual Property Officer. Under her leadership, we just reached a key milestone, with 302 active utility and design patent documents, more than double compared to the 149 we announced at the Q2 report in August 2021.'
META's patent portfolio comprises 175 issued patents, including one design patent, and 127 pending patent applications, in 81 patent families, of which 48 include at least one granted patent. There are 15 active patent documents for glucoWISE®, including 5 issued patents, within 6 patent families, of which 3 include at least one issued patent.
About Meta Materials Inc.
META® delivers previously unachievable performance, across a range of applications, by inventing, designing, developing, and manufacturing sustainable, highly functional materials. Our extensive technology platform enables leading global brands to deliver breakthrough products to their customers in consumer electronics, 5G communications, health and wellness, aerospace, automotive, and clean energy. Our nano-optic technology provides anti-counterfeiting security features for government documents and currencies and authentication for brands. Our achievements have been widely recognized, including being named a Lux Research Innovator of the Year in 2021. Learn more at www.metamaterial.com.
This press release includes forward-looking information or statements within the meaning of Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, regarding the Company, which may include, but are not limited to, statements with respect to the business strategies, product development, expansion plans and operational activities of the Company. Often but not always, forward-looking information can be identified by the use of words such as 'pursuing', 'potential', 'predicts', 'projects', 'seeks', 'plans', 'expect', 'intends', 'anticipated', 'believes' or variations (including negative variations) of such words and phrases, or statements that certain actions, events or results 'may', 'could', 'should', 'would' or 'will' be taken, occur or be achieved. Such statements are based on the current expectations and views of future events of the management of the Company and are based on assumptions and subject to risks and uncertainties. Although the management of the Company believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, the capabilities of our facilities and the expansion thereof, research and development projects of the Company, the market potential of the products of the Company , the market position of the Company, the scalability of the Company's production ability, capacity for new customer engagements, material selection programs timeframes, the ability to reduce production costs, enhance metamaterials manufacturing capabilities and extend market reach into new applications and industries, the ability to accelerate commercialization plans, the possibility of new customer contracts, the continued engagement of our employees, the technology industry, market strategic and operational activities, and management's ability to manage and to operate the business. More details about these and other risks that may impact the Company's businesses are described under the heading 'Forward-Looking Information' and under the heading 'Risk Factors' in the Company's Form 10-K filed with the SEC on March 1, 2022, with an SEC filing date of March 2, in the Company's Form 10-Q filed with the SEC on May 10, 2022, and in subsequent filings made by Meta Materials with the SEC, which are available on SEC's website at www.sec.gov. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except to the extent required by law.
Vice President, Corporate Development and Communications
Meta Materials Inc.
Senior Vice President
SOURCE: Meta Materials Inc.
View source version on accesswire.com: https://www.accesswire.com/701229/Meta-Materials-Announces-First-Granted-US-Patent-for-Non-Invasive-Glucose-Sensing-System